Europabio

EFIB Den Haag Statement - A modernised European Union for Industrial Biotechnology
2026-07-13 10:00 - 11:00 (Europe/Brussels)
EuropaBio’s EFIB Statement presents three clear asks for the European Union:

Ask 1 – Modernising regulation and policy: A dedicated, horizontal EU Regulation for Microorganisms

Ask 2 – Education and awareness: Future-looking stakeholder engagement and Representation

Ask 3 – Financing innovation: Delivering a mature funding and collaborative framework

These asks sit within a progressive legislative mandate for industrial biotechnology and microorganisms. It supports the translation of a competitiveness agenda into legislation that delivers the bioeconomy.

Join EuropaBio for a deep dive into the EFIB Statement and what it means for innovation and manufacturing in the European Union?

AGENDA

Presentation of the EFIB statement: Claire Skentelbery, Director General, EuropaBio

Fireside chat: Giovanni Colombo, Group Senior Director Public Affairs, dsm-firmenich and Board Member EuropaBio

Register Here

Prague.bio Conference 2026
2026-09-23 08:00 - 20:00
Join our Director General Dr Claire Skentelbery at the 4th edition of Prague.bio Conference!

If you want to meet and network with biotech leaders shaping the CEE region, Prague.bio Conference 2026 is the place to be

Expect 400+ participants, partnering via the conference app, inspiring keynotes, panel discussions, hands-on workshops, and pitch & poster sessions.

More Info Here & Tickets

World Orphan Drug Congress 2026
2026-10-26 08:00 - 2026-10-28 20:00
The World Orphan Drug Congress Europe is the largest and most established event globally for orphan drugs and rare diseases.

Join over 1,800 senior industry leaders, gain insights from 250+ expert speakers, and connect with over 100 exhibitors driving progress across the entire orphan drug lifecycle. From regulatory strategy and market access to patient engagement and the latest breakthroughs in gene and cell therapies, the congress delivers practical insights you can apply immediately.

Network with the most senior individuals across the industry, including leaders in R&D, gene therapy, rare diseases, precision/personalised medicine, genetic disorders, patient advocacy and engagement, associations in ATMPs, investors, regulatory affairs professions, governmental bodies, and more…

More Info Here
